Cancer
Breast cancer in Guangzhou
广州 乳腺癌
17 hospitals in Guangzhou
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Guangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 222 papers led
- 135 papers led
- 96 papers led
- 83 papers led
- 57 papers ledNo open trial led
- 50 papers led
- First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院International Medical Center, Nansha campus49 papers led
- 30 papers ledNo open trial led
- 24 papers ledNo open trial led
- 20 papers ledNo open trial led
- 19 papers ledNo open trial led
- 16 papers led
- 16 papers led
- 13 papers ledNo open trial led
- 8 papers led
- 4 papers ledNo open trial led
- 0 papers ledNo open trial led
Breast cancer in every city Guangzhou on the disease page, with the national map
open trials on breast cancer with a hospital in Guangzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Guangzhou as lead sponsor or study site. 85 of them are led by a hospital in Guangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07281976
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Guangzhou, Harbin, Nanjing, Shenyang, Zhengzhou
- RecruitingA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07347600
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Novel Intraoperative Fluorescence-guided System for Evaluating Margins During Breast-conserving Surgery for Breast Cancer
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07352930
Age 18 years to Not stated; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingFMD and Neoadjuvant Chemo-immunotherapy in TNBC
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07378306
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingRibociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07400523
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 2 listed hospitals as study sitesGuangzhou, Shantou, Zhanjiang
- RecruitingEfficacy and Safety of Hyperbaric Oxygen Therapy in Improving Nab-paclitaxel-Induced Peripheral Neuropathy
- Phase
- Phase 2/Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07410169
Age 18 years to 75 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07413939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07498478
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan
- RecruitingLarge Language Models Assist in Tumor MDT
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07504367
Age 25 years to 33 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07518173
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingA Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07520760
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07533123
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingMegestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer
- Phase
- Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07543536
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07544056
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingDalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07610720
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingClinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07697443
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chengdu, Guangzhou, Meizhou, Tianjin, Wuhan
- RecruitingSMP-656 for HER2-Positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07726342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou
- RecruitingCulmerciclib in HR+/HER2+ Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07732491
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07757230
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- RecruitingNeoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07796880
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC)
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07876557
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Jinan, Lanzhou, Nanchang, Nanjing, Qingdao, Shenyang, Shijiazhuang, Taiyuan, Weifang, Wuhan, Yinchuan, Zhengzhou
- RecruitingMultimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
- Phase
- Not given
- Started
- 2026-10
- Posted
- Registry
- NCT07880106
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Phase II Clinical Trial of Artificial Intelligence-assisted One-stop Radiotherapy for Breast Cancer After Breast-conserving Surgery
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06686459
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06756932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06790693
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang
- RecruitingA Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06811870
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06841354
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingThe Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer.
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06851299
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPhase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06889688
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingProbiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT06892093
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingBortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT06900647
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingStudy on the Use of Lateral Decubitus Position in Left Breast Cancer Patients Undergoing Adjuvant Radiotherapy
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06902051
Age 18 years to 70 years; women only (registered criteria)
Led by Nanfang HospitalGuangzhou
- RecruitingA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06926868
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingA Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-05
- Posted
- Registry
- NCT06957886
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingCirculating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06992336
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06993844
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Shanghai
- RecruitingThe Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06995118
Age 18 years to 70 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Guangzhou, Nanchang, Zhengzhou
- RecruitingA Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07024173
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangsha, Guangzhou
- RecruitingEfficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07037199
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07060807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07062965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an
- RecruitingModulating the Skin Microbiome to Prevent Radiation Dermatitis in Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT07066280
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07071337
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingAdaptive Chemotherapy for the Treatment of Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07088263
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07095023
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Guiyang, Shantou, Shenzhen, Wenzhou
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07174336
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan
- RecruitingSac-TMT Plus KL-A167 in PD-L1+, HR+/HER2- Metastatic Breast Cancer After CDK4/6 Inhibitors
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07258108
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Retrospective Analysis of Robot-Assisted Versus Endoscopic Breast-Conserving Surgery for Breast Cancer
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT07321145
Age 18 years to 80 years; women only (registered criteria)
Led by Sixth Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingEfficacy and Safety of Trastuzumab-rezetecan in HER2-Expressing Breast Cancer
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07358182
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingAcupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07377279
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy and Safety of Extended-Dose Interval Immunotherapy Versus Standard-Dose Interval Immunotherapy for Advanced Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07401537
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEndoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07548762
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingOrganoid-based Functional Precision Therapy for Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06102824
Age 18 years to 80 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT06172478
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Guangzhou
- RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06210776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai
- RecruitingRandomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2024-06
- Posted
- Registry
- NCT06255392
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06313463
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingMinimal Access Versus Conventional Latissimus Dorsi Flap Harvest for Breast Reconstruction
- Phase
- N/A
- Started
- 2024-03
- Posted
- Registry
- NCT06319157
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingThe Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery
- Phase
- Not given
- Started
- 2024-02
- Posted
- Registry
- NCT06425874
Age 18 years to 50 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingPARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC
- Phase
- Phase 3
- Started
- 2024-08
- Posted
- Registry
- NCT06533384
Age 18 years to 70 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- RecruitingThe Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
- Phase
- Phase 4
- Started
- 2024-10
- Posted
- Registry
- NCT06641544
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingArsenous Acid for Refractory Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06678048
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingLong-Term Outcomes of Endoscopic-assisted vs Conventional Breast-conserving Surgery in Breast Cancer Patients After Neoadjuvant Therapy: a Randomized, Multicenter, Open Label, Non-inferiority Trial
- Phase
- N/A
- Started
- 2024-08
- Posted
- Registry
- NCT06716073
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingThe Optimal Radioimmunotherapy Combinations for Advanced TNBC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06735131
Age not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05646862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingPhase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-04
- Posted
- Registry
- NCT05744687
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesAnyang, Beijing, Changchun, Fuzhou, Guangzhou, Luoyang, Yinchuan
- RecruitingAdjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT05760612
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05860465
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan
- RecruitingEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05872347
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou
- RecruitingEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05891093
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingDisitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
- Phase
- Phase 3
- Started
- 2023-07
- Posted
- Registry
- NCT05904964
Age 18 years to 70 years (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou, Shantou
- RecruitingStudy of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05909332
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingStudy of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05981001
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05981014
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
- RecruitingBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06120283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang
- RecruitingPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06121557
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingPhase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
- Phase
- Phase 1
- Started
- 2023-11
- Posted
- Registry
- NCT06121570
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingClinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06167694
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Guangzhou
- RecruitingDisitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT06278870
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingAI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes Tumors
- Phase
- Not given
- Started
- 2023-03
- Posted
- Registry
- NCT06286267
Age not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 1 listed hospital as study siteGuangzhou
- RecruitingEGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
- Phase
- Early phase 1
- Started
- 2022-05
- Posted
- Registry
- NCT05341492
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05461768
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Wuhan, Zhengzhou
- RecruitingA Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05470348
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingNeoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
- Phase
- Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05761470
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou
- RecruitingA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05851014
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou
- RecruitingCold Dissection Versus Electrocautery Dissection in Endoscopic Nipple-Sparing Mastectomy and Immediate Implant-Based Reconstruction: A Randomized Controlled Trial
- Phase
- N/A
- Started
- 2022-11
- Posted
- Registry
- NCT06024187
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT06551220
Age 18 years to 80 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai
- RecruitingRegional Radiotherapy Omission in Low-Risk Node Positive Breast Cancer
- Phase
- Not given
- Started
- 2022-07
- Posted
- Registry
- NCT07179744
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStandard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2021-04
- Posted
- Registry
- NCT04722978
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
- RecruitingA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
- Phase
- Phase 2/Phase 3
- Started
- 2021-04
- Posted
- Registry
- NCT04803539
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingEngineered TILs/CAR-TILs to Treat Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2021-01
- Posted
- Registry
- NCT04842812
Age 18 years to 85 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingNeoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2021-12
- Posted
- Registry
- NCT05159193
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingTriplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2021-11
- Posted
- Registry
- NCT05187338
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
- Phase
- Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04501523
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Phase
- Phase 2
- Started
- 2020-11
- Posted
- Registry
- NCT04606446
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Xi'an
- RecruitingFulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2020-10
- Posted
- Registry
- NCT04646759
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingRecurIndex Guided Avoidance of Regional Nodal Irradiation for Node Positive Breast Cancer
- Phase
- N/A
- Started
- 2019-08
- Posted
- Registry
- NCT04069884
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- RecruitingTrans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
- Phase
- Phase 2/Phase 3
- Started
- 2018-11
- Posted
- Registry
- NCT03755739
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital of Guangzhou Medical UniversityGuangzhou
- RecruitingFulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2018-05
- Posted
- Registry
- NCT04263298
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Shenzhen, Zhanjiang
- Not yet recruitingA Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07235618
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingBone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07255612
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingPedicled Lateral Chest Wall Lymph-Adipofascial Flap to Prevent Arm Lymphedema After Breast Cancer Surgery
- Phase
- N/A
- Started
- 2026-02
- Posted
- Registry
- NCT07415200
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingEffects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07533526
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07539753
Age 18 years to 75 years; women only (registered criteria)
Led by Nanfang HospitalGuangzhou
- Not yet recruitingUltrasound Monitoring of Clipped Lymph Nodes to Predict Axillary Response After Chemotherapy in Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07596472
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingEfficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07630103
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingMolecular Subtype-Guided Postoperative Radiotherapy for Phyllodes Tumor of the Breast
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07657169
Age 18 years to 75 years; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 3 listed hospitals as study sitesGuangzhou, Jinan, Qingdao, Shenzhen
- Not yet recruitingCulmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07745257
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou
- Not yet recruitingResearch on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models
- Phase
- Not given
- Started
- 2026-09
- Posted
- Registry
- NCT07767565
Age 18 years to 75 years (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingImpact of Robotic Versus Endoscopic Surgery on Nipple Nerve Function Following Nipple-Sparing Mastectomy for Breast Cancer
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07850154
Age not stated (registered criteria)
Led by Guangzhou Women and Children's Medical CenterGuangzhou
- Not yet recruitingA Drug-Drug Interaction Study of Rifampicin and Oral HRS-8080
- Phase
- Phase 1
- Started
- 2026-11
- Posted
- Registry
- NCT07876596
Age 18 years to 55 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteGuangzhou
- Not yet recruitingTrastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2026-11
- Posted
- Registry
- NCT07892274
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingMultimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning
- Phase
- Not given
- Started
- 2026-11
- Posted
- Registry
- NCT07943494
Age not stated (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingThis Study Aims to Explore the Efficacy of Hyperbaric Oxygen in the Treatment of Flap Ischaemic Necrosis After Breast Cancer Surgery
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06811857
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingHyperbaric Oxygen Therapy for Peripheral Neuropathy Due to Paclitaxel Analogs
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06819501
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Hormone Receptor Positive Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06825949
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Triple-Negative and HER2+ Breast Cancer Patients
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06825975
Age 18 years to 60 years; women only (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingA Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07040644
Age 18 years to Not stated; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingHuman-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component
- Phase
- N/A
- Started
- 2025-08
- Posted
- Registry
- NCT07060599
Age not stated; women only (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingComparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07061717
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Not yet recruitingFasting-Mimicking Diet as an Adjunct to Neoadjuvant Chemotherapy for Hormone-Receptor-Positive Breast Cancer
- Phase
- N/A
- Started
- 2025-07
- Posted
- Registry
- NCT07077018
Age 18 years to 75 years (registered criteria)
Led by Guangdong Provincial People's HospitalGuangzhou
- Not yet recruitingEvaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07246317
Age 18 years to 70 years; women only (registered criteria)
Led by Tianjin Medical University Cancer Institute & Hospital; 4 listed hospitals as study sitesGuangzhou, Luoyang, Shijiazhuang, Tianjin
- Not yet recruitingMyeloprotection With Trilaciclib in Pan-cancer Population
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06297811
Age 18 years to Not stated (registered criteria)
Led by Sun Yat-sen University Cancer CenterGuangzhou
- Not yet recruitingAromatherapy in the Treatment of Early Breast Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06435104
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Enrolling by invitationEndoscopic Nipple-Sparing Mastectomy (E-NSM) With Immediate Multistage Autologous Fat Grafting(IMAFG) for Total Breast Reconstruction Via the Axillary Incision
- Phase
- N/A
- Started
- 2026-01
- Posted
- Registry
- NCT07352137
Age 18 years to 70 years; women only (registered criteria)
Led by Guangdong Provincial Hospital of Chinese MedicineGuangzhou
- Enrolling by invitationTrastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II Study
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06843681
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial HospitalGuangzhou
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Guangzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Brain Hospital of Guangzhou Medical University广州医科大学附属脑科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Cancer Hospital of Guangzhou Medical University广州医科大学附属肿瘤医院 | 291 open | 1 | 31 | 18 | 28 | none | 30 | 15 | none | none | none | 0 | none | 1 | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital of Southern China University of Technology华南理工大学医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Affiliated Hospital, Sun Yat-sen University中山大学附属口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Air Force Hospital中国人民解放军南部战区空军医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children Hospital广东省妇幼保健院 | none | none | none | none | none | none | 13 | none | none | none | none | 1 | none | 0 | 1 | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 2 | none | none | none | none | none | none | none | |
| Children's Medical Center广州医科大学附属妇女儿童医疗中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | |
| Clifford Hospital | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Dermatology Hospital上海市皮肤病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | |
| Dermatology Hospital, Southern Medical University南方医科大学皮肤病医院、广东省皮肤病医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | |
| Eighth People's Hospital of Guangzhou Affiliated to Guangzhou Medical College广州医科大学附属市八医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Guangzhou Medical University广州医科大学附属第五医院 | 1 | 5 | none | none | 22 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Fifth Affiliated Hospital of Southern Medical University南方医科大学第五附属医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Guangdong Pharmaceutical University广东药科大学附属第一医院 | 4 | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Guangzhou Medical University广州医科大学附属第一医院 | 6 | 3 | none | none | 18621 open | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 0 | 0 | none | 21 | 3 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | 0 | none | none | none | none | |
| First Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第一附属医院 | 2 | none | 32 | 12 | 35 | none | 4 | none | none | none | none | 2 | none | none | none | 2 | none | none | none | 7 | 0 | 0 | none | none | none | none | none | 6 | none | none | none | 4 | none | none | none | 1 | none | 4 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Jinan University暨南大学附属第一医院 | 16 | 5 | 451 open | 21 | 59 | none | 57 | 30 | none | 0 | none | 9 | 1 | 2 | none | 5 | none | none | none | 5 | 2 | none | none | none | none | none | none | 4 | none | 2 | none | 7 | 6 | none | 0 | none | none | 1 | none | none | none | none | none | none | none | 1 | 0 | none | none | none | none | none | none | 2 | 2 | none | none | none | none | none | none | |
| First Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院 | 143 open | 201 open | 2196 open | 52 | 71 | 39 | 491 open | 391 open | 5 | 1 | 0 | 33 | 92 open | 0 | 1 | 18 | 1 | none | 2 | 3 | 5 | none | none | none | none | 2 | none | 28 | 4 | 6 | 12 | 211 open | 61 open | 5 | 2 | 0 | 1 | 9 | none | 2 | 4 | 0 | 0 | 5 | 4 | 0 | 222 open | 0 | none | none | 1 | 0 | none | 1 | none | 0 | 0 | none | none | none | none | |
| Fuda Cancer Hospital广州复大肿瘤医院 | 0 | none | 0 | 0 | 0 | 0 | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Clifford Hospital广东祈福医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Province Hospital for Occupational Disease Prevention and Treatment广东省职业病防治院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial Hospital of Chinese Medicine广东省中医院 | 5 | none | 25 | 12 | 41 | 6 | 501 open | 12 | none | none | none | 2 | 1 | 3 | 1 | none | none | none | none | none | 0 | none | none | none | none | 4 | none | 0 | none | none | none | 15 | 7 | none | 0 | none | none | 2 | 1 | 4 | none | none | none | none | none | none | 6 | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial People's Hospital广东省人民医院 | 14 | 19 | 541 open | 211 open | 23619 open | 441 open | 9610 open | 43 | 1 | 2 | 1 | 11 | 1 | 0 | none | 3 | 1 | none | none | 23 | 1 | none | none | none | none | 3 | 3 | 1 | none | none | none | 652 open | 80 | none | none | 0 | none | 2 | none | 1 | none | 1 | none | none | 1 | none | 81 open | none | none | none | 4 | 1 | none | none | none | none | none | none | none | none | none | |
| Guangdong Provincial Second Hospital广东省第二中医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangdong Second Provincial General Hospital广东省第二人民医院 | 3 | none | 16 | none | none | none | none | none | none | none | none | 2 | none | 1 | none | 31 open | none | none | 2 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | 1 | none | 1 | none | none | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Chest Hospital广州市胸科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Dongsheng Hospital广州市东升医院(广州市老年病康复医院) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Eighth People's Hospital广州市第八人民医院(嘉禾院区) | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Guangzhou First People's Hospital广州市第一人民医院 | 4 | none | 22 | 12 | none | 11 | 20 | none | none | none | none | 4 | 0 | 1 | none | 0 | none | 13 | none | 7 | 1 | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | 4 | 1 | none | 2 | none | none | none | none | none | 2 | none | none | 1 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou General Hospital中国人民解放军南部战区总医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Hospital广州市中西医结合医院 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Orthopedics Hospital广州市正骨医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Panyu Central Hospital广州医科大学附属番禺中心医院 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangzhou Red Cross Hospital广州市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Guangzhou Women and Children's Medical Center广州市妇女儿童医疗中心 | 2 | none | none | none | 5 | none | 161 open | 13 | 9 | 3 | none | 1 | 0 | 321 open | none | none | 21 open | none | none | none | 191 open | 0 | none | none | none | 1 | none | none | none | 2 | 19 | 7 | 34 | 2 | 3 | none | none | 1 | none | 0 | none | none | 1 | 2 | none | 2 | 0 | 1 | none | 1 | none | 0 | 11 | 7 | none | none | none | none | none | none | none | |
| Hexian Memorial Hospital广州市番禺区妇幼保健院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | |
| Huadu Distinct People's Hospital广州市花都区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Integrated Hospital, Southern Medical University南方医科大学中西医结合医院 | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Nanfang Hospital南方医科大学南方医院 | 336 open | 84 open | 1277 open | 12812 open | 835 open | 8 | 832 open | 531 open | 0 | 0 | none | 6 | 2 | 2 | none | 3 | 8 | none | none | 19 | 21 | 9 | 1 | none | none | 3 | none | 1 | 6 | none | none | 13 | 1 | 0 | 7 | none | none | 5 | none | 6 | 1 | 2 | none | 0 | none | 0 | 51 open | none | none | none | 1 | none | 1 | 0 | none | none | 2 | none | none | none | none | |
| Panyu Hospital广州市番禺区中医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Guangzhou Medical University广州医科大学附属第二医院 | 4 | none | 3918 open | 41 open | 1315 open | 64 open | 84 open | 14 | none | none | none | 1 | none | 1 | none | 5 | 0 | none | none | 2 | 2 | 0 | none | none | none | 2 | none | none | none | none | none | none | 4 | none | 0 | none | none | 3 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | |
| Sixth Affiliated Hospital of Guangzhou Medical University清远市人民医院 | 3 | none | none | none | none | none | none | 12 | none | none | none | 2 | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Sixth Affiliated Hospital of Sun Yat-sen University中山大学附属第六医院 | none | 0 | none | 455 open | none | 7 | 161 open | none | none | 0 | none | 1 | 3 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 4 | 1 | none | none | none | 1 | none | 0 | 1 | none | 0 | none | none | none | none | |
| Sun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院 | 255 open | 102 open | 6610 open | 115 open | 362 open | 34 | 13548 open | 11 | 2 | none | none | 6 | 0 | 101 open | 2 | 1 | 4 | none | 4 | 7 | 6 | none | none | none | none | 01 open | 4 | none | none | none | none | 29 | 2 | 4 | none | none | 1 | none | none | 3 | none | none | none | none | 1 | none | 7 | none | none | 0 | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Sun Yat-sen University Cancer Center中山大学肿瘤防治中心 | 48357 open | 1378 open | 28118 open | 1034 open | 35732 open | 553 open | 22217 open | 621 open | 01 open | none | 0 | 191 open | 2 | 75 open | 31 open | 16 | 3 | none | 1 | 14225 open | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Guangzhou Medical University广州医科大学附属第三医院 | 4 | none | none | none | none | 20 | none | none | none | none | none | 4 | none | 0 | none | none | none | none | none | none | 5 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | |
| Third Affiliated Hospital of Guangzhou University of Chinese Medicine广州中医药大学第三附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Southern Medical University南方医科大学第三附属医院 | 8 | none | none | none | none | none | none | none | none | none | none | 9 | none | none | 0 | 31 open | none | none | none | 21 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Sun Yat-sen University中山大学附属第三医院 | 10 | none | 1713 open | 15 | none | 6 | 19 | none | 1 | none | none | 2 | 0 | 1 | none | 4 | none | none | 1 | 6 | 0 | none | none | none | 1 | 392 open | none | 01 open | 3 | 0 | none | 9 | none | 4 | 22 | 2 | none | 1 | none | 2 | none | none | none | none | 0 | 1 | 0 | none | 0 | none | 2 | 1 | none | none | none | 0 | none | none | none | none | none | |
| Third People's Hospital, Guangzhou Medical University | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Ophthalmic Center中山大学中山眼科中心 | none | none | none | none | none | none | none | none | none | 251 open | none | none | none | 0 | none | none | none | none | none | 41 open | none | none | none | none | none | 4 | none | none | none | none | none | none | 8 | 1 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | |
| Zhujiang Hospital南方医科大学珠江医院 | 11 | 4 | 545 open | 10 | 691 open | 21 | 24 | 661 open | none | 1 | 1 | 9 | none | 6 | none | 23 open | 12 open | none | none | 101 open | 1 | none | none | none | none | none | none | none | none | none | none | 7 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 2 | none | none | none | none | none | none | 5 | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Guangzhou.
- Nasopharyngeal carcinoma 6
- Oesophageal squamous cell carcinoma 3
- Lung cancer 18621 open
- Osteosarcoma 0
- Neuroblastoma 1
- Lymphoma 1
- Congenital heart disease 2
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 21
- Lymphangioleiomyomatosis 3
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 16
- Oesophageal squamous cell carcinoma 5
- Hepatocellular carcinoma 451 open
- Stomach cancer 21
- Lung cancer 59
- Breast cancer 57
- Glioma 30
- Retinoblastoma 0
- Osteosarcoma 9
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Multiple myeloma 5
- Lymphoma 5
- Beta thalassaemia 2
- Myasthenia gravis 4
- Wilson disease 2
- Coronary heart disease 7
- Congenital heart disease 6
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 1
- Alport syndrome 1
- IgA nephropathy 0
- Hirschsprung disease 2
- Inherited epidermolysis bullosa 2
- Nasopharyngeal carcinoma 143 open
- Oesophageal squamous cell carcinoma 201 open
- Hepatocellular carcinoma 2196 open
- Stomach cancer 52
- Lung cancer 71
- Pancreatic cancer 39
- Breast cancer 491 open
- Glioma 391 open
- Hepatoblastoma 5
- Retinoblastoma 1
- Chordoma 0
- Osteosarcoma 33
- Gastrointestinal stromal tumour 92 open
- Neuroblastoma 0
- Ewing sarcoma 1
- Multiple myeloma 18
- B-cell acute lymphoblastic leukaemia 1
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 3
- Beta thalassaemia 5
- Neuromyelitis optica spectrum disorder 2
- Myasthenia gravis 28
- Moyamoya disease 4
- Wilson disease 6
- Biliary atresia 12
- Coronary heart disease 211 open
- Congenital heart disease 61 open
- Scoliosis 5
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Hepatic echinococcosis 1
- Idiopathic pulmonary fibrosis 9
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 4
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 5
- Behçet disease 4
- Alport syndrome 0
- IgA nephropathy 222 open
- Gaucher disease 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Hirschsprung disease 1
- Hereditary angioedema 0
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 5
- Hepatocellular carcinoma 25
- Stomach cancer 12
- Lung cancer 41
- Pancreatic cancer 6
- Breast cancer 501 open
- Glioma 12
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Neuroblastoma 3
- Ewing sarcoma 1
- Beta thalassaemia 0
- Neuromyelitis optica spectrum disorder 4
- Myasthenia gravis 0
- Coronary heart disease 15
- Congenital heart disease 7
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 2
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 4
- IgA nephropathy 6
- Primary biliary cholangitis 2
- Nasopharyngeal carcinoma 14
- Oesophageal squamous cell carcinoma 19
- Hepatocellular carcinoma 541 open
- Stomach cancer 211 open
- Lung cancer 23619 open
- Pancreatic cancer 441 open
- Breast cancer 9610 open
- Glioma 43
- Hepatoblastoma 1
- Retinoblastoma 2
- Chordoma 1
- Osteosarcoma 11
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Multiple myeloma 3
- B-cell acute lymphoblastic leukaemia 1
- Lymphoma 23
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 3
- IgG4-related disease 3
- Myasthenia gravis 1
- Coronary heart disease 652 open
- Congenital heart disease 80
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Behçet disease 1
- IgA nephropathy 81 open
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 1
- Nasopharyngeal carcinoma 4
- Hepatocellular carcinoma 22
- Stomach cancer 12
- Pancreatic cancer 11
- Breast cancer 20
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 0
- Aplastic anaemia 13
- Lymphoma 7
- Beta thalassaemia 1
- Thrombotic thrombocytopenic purpura 1
- Fanconi anaemia 1
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Duchenne muscular dystrophy 2
- IgA nephropathy 1
- Gaucher disease 0
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 2
- Lung cancer 5
- Breast cancer 161 open
- Glioma 13
- Hepatoblastoma 9
- Retinoblastoma 3
- Osteosarcoma 1
- Gastrointestinal stromal tumour 0
- Neuroblastoma 321 open
- B-cell acute lymphoblastic leukaemia 21 open
- Beta thalassaemia 191 open
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 1
- Wilson disease 2
- Biliary atresia 19
- Coronary heart disease 7
- Congenital heart disease 34
- Scoliosis 2
- Anti-NMDA receptor encephalitis 3
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 0
- Pompe disease 1
- Duchenne muscular dystrophy 2
- Alport syndrome 2
- IgA nephropathy 0
- Gaucher disease 1
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 11
- Hirschsprung disease 7
- Nasopharyngeal carcinoma 336 open
- Oesophageal squamous cell carcinoma 84 open
- Hepatocellular carcinoma 1277 open
- Stomach cancer 12812 open
- Lung cancer 835 open
- Pancreatic cancer 8
- Breast cancer 832 open
- Glioma 531 open
- Hepatoblastoma 0
- Retinoblastoma 0
- Osteosarcoma 6
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Multiple myeloma 3
- B-cell acute lymphoblastic leukaemia 8
- Lymphoma 19
- Beta thalassaemia 21
- Haemophilia A 9
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 3
- Myasthenia gravis 1
- Moyamoya disease 6
- Coronary heart disease 13
- Congenital heart disease 1
- Scoliosis 0
- Anti-NMDA receptor encephalitis 7
- Idiopathic pulmonary fibrosis 5
- Amyotrophic lateral sclerosis 6
- Spinal muscular atrophy 1
- Fabry disease 2
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 51 open
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 0
- Familial adenomatous polyposis 2
- Nasopharyngeal carcinoma 4
- Hepatocellular carcinoma 3918 open
- Stomach cancer 41 open
- Lung cancer 1315 open
- Pancreatic cancer 64 open
- Breast cancer 84 open
- Glioma 14
- Osteosarcoma 1
- Neuroblastoma 1
- Multiple myeloma 5
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 2
- Beta thalassaemia 2
- Haemophilia A 0
- Neuromyelitis optica spectrum disorder 2
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 3
- IgA nephropathy 0
- Hereditary angioedema 0
- Oesophageal squamous cell carcinoma 0
- Stomach cancer 455 open
- Pancreatic cancer 7
- Breast cancer 161 open
- Retinoblastoma 0
- Osteosarcoma 1
- Gastrointestinal stromal tumour 3
- Beta thalassaemia 1
- Behçet disease 1
- IgA nephropathy 4
- Gaucher disease 1
- Primary sclerosing cholangitis 1
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 255 open
- Oesophageal squamous cell carcinoma 102 open
- Hepatocellular carcinoma 6610 open
- Stomach cancer 115 open
- Lung cancer 362 open
- Pancreatic cancer 34
- Breast cancer 13548 open
- Glioma 11
- Hepatoblastoma 2
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Neuroblastoma 101 open
- Ewing sarcoma 2
- Multiple myeloma 1
- B-cell acute lymphoblastic leukaemia 4
- Haemophagocytic lymphohistiocytosis 4
- Lymphoma 7
- Beta thalassaemia 6
- Neuromyelitis optica spectrum disorder 01 open
- IgG4-related disease 4
- Coronary heart disease 29
- Congenital heart disease 2
- Scoliosis 4
- Hepatic echinococcosis 1
- Amyotrophic lateral sclerosis 3
- Behçet disease 1
- IgA nephropathy 7
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Nasopharyngeal carcinoma 48357 open
- Oesophageal squamous cell carcinoma 1378 open
- Hepatocellular carcinoma 28118 open
- Stomach cancer 1034 open
- Lung cancer 35732 open
- Pancreatic cancer 553 open
- Breast cancer 22217 open
- Glioma 621 open
- Hepatoblastoma 01 open
- Chordoma 0
- Osteosarcoma 191 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 75 open
- Ewing sarcoma 31 open
- Multiple myeloma 16
- B-cell acute lymphoblastic leukaemia 3
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 14225 open
- Beta thalassaemia 1
- Fanconi anaemia 0
- Idiopathic pulmonary fibrosis 2
- Nasopharyngeal carcinoma 10
- Hepatocellular carcinoma 1713 open
- Stomach cancer 15
- Pancreatic cancer 6
- Breast cancer 19
- Hepatoblastoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Multiple myeloma 4
- Haemophagocytic lymphohistiocytosis 1
- Lymphoma 6
- Beta thalassaemia 0
- Fanconi anaemia 1
- Neuromyelitis optica spectrum disorder 392 open
- Myasthenia gravis 01 open
- Moyamoya disease 3
- Wilson disease 0
- Coronary heart disease 9
- Scoliosis 4
- Anti-NMDA receptor encephalitis 22
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 0
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 2
- Primary sclerosing cholangitis 1
- Hereditary angioedema 0
- Nasopharyngeal carcinoma 11
- Oesophageal squamous cell carcinoma 4
- Hepatocellular carcinoma 545 open
- Stomach cancer 10
- Lung cancer 691 open
- Pancreatic cancer 21
- Breast cancer 24
- Glioma 661 open
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 9
- Neuroblastoma 6
- Multiple myeloma 23 open
- B-cell acute lymphoblastic leukaemia 12 open
- Lymphoma 101 open
- Beta thalassaemia 1
- Coronary heart disease 7
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 2
- Hirschsprung disease 5
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Guangzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.